Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China
Table 1
Clinical characteristics of HER2-positive breast cancer from China and the United States.
Variables
China (N = 918)
The United States (N = 24773)
value
Age at diagnosis
46 (range, 23 to 78)
58 (range, 17 to 102)
<0.0001
Pathological type (%)
0.079
Ductal or lobular invasive carcinoma
880 (95.9)
24173 (97.6)
Others
26 (2.8)
600 (2.4)
Unknown
12 (1.3)
0
Histopathologic grade (%)
<0.0001
Grade I
15 (1.6)
1234 (5.0)
Grade II
306 (33.3)
9030 (36.5)
Grade III
203 (22.1)
14393 (58.1)
Unknown
394 (42.9)
116 (0.4)
Molecular features
ER (%)
<0.0001
Positive
470 (51.1)
16973 (68.5)
Negative
419 (45.6)
7784 (31.4)
Unknown
30 (3.3)
16 (0.1)
PR (%)
<0.0001
Positive
447 (48.7)
12893 (52.0)
Negative
464 (50.5)
11832 (47.8)
Unknown
7 (0.8)
48 (0.2)
Molecular phenotype
<0.0001
HR + HER2+
505 (55.0)
17538 (70.8)
HR-HER2+
397 (43.2)
7235 (29.2)
Unknown
16 (1.7)
0
OS (average, months)
30.16
36.12
ER, estrogen receptor; PR, progesterone receptor; HR, hormonal receptor; HER2, human epidermal growth factor receptor 2; OS, overall survival.
